AAN 2021 | The efficacy and safety of SEP-363856 for Parkinson’s disease psychosis

Stuart Isaacson, MD, FAAN, Parkinson Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, discusses the study (NCT02969369) evaluating the efficacy and safety of SEP-363856,a non–D2-receptor binding drug with antipsychotic activity, for Parkinson’s disease (PD) psychosis presented at the American Academy of Neurology (AAN) 2021 Annual Meeting. The study analyzed patients with psychosis symptoms at baseline treated for six weeks with placebo or the SEP-363856 medication. The results suggested an improvement in symptoms without affecting the dopamine receptors, with 25% of patients that received the medication presenting a complete response. Dr Isaacson also comments on the next steps of the study. This interview took place during the AAN 2021 Annual Meeting.